子類別 期刊論文 [327/330] 圖書 [1/1] 會議論文/會議摘要 [115/179] 鄰近社群 于重元 [19/19] 劉柯俊 [85/98] 劉滄梧 [119/125] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [82/94] 常慧如 [39/44] 張俊彥 [234/254] 張光裕 [69/79] 張憶壽 [103/106] 張文祥 [52/53] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/43] 李家惠 [29/29] 李岳倫 [48/49] 林素芳 [32/32] 楊奕馨 [41/42] 江士昇 [88/90] 沈哲宏 [14/16] 洪文俊 [88/88] 莊雙恩 [82/91] 蔡坤志 [32/34] 蔡慧珍 [66/71] 蘇勇曄 [40/40] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [45/48] 陳振陽 [72/72] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [38/39] 黃智興 [55/55] 黃道揚 [26/26] 丁兆治(2000-2004) [5/5] 其他 [464/471] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/55] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群統計 近3年內發表的文件:74(14.51%) 含全文筆數:443(86.86%) 文件下載次數統計 下載大於0次:443(100.00%) 下載大於100次:424(95.71%) 檔案下載總次數:176904(3.30%) 最後更新時間: 2024-11-28 13:36 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati... Survival of advanced/recurrent gast... Topiramate suppresses peri-infarct ... A phase 1 study of biweekly nab-pac... Plain language summary of the FOENI... Outcomes of post-immunotherapy dura... Durvalumab or placebo plus gemcitab... Impact of previous S-1 treatment on... Chromatin remodeling-related PRDM1 ...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目101-125 / 510. (共21頁) << < 1 2 3 4 5 6 7 8 9 10 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2021-04	Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors	Oncologist. 2021 Apr;26(4):e567-e579.
2021-03-01	Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors	Scientific Reports. 2021 Mar 1;11:Article number 4834.
2021-03	A phase II clinical trial on the combination therapy of PHY906 plus capecitabine in hepatocellular carcinoma	Oncologist. 2021 Mar;26(3):e367-e373.
2021-01-13	Development of possible next line of systemic therapies for gemcitabine-resistant biliary tract cancers: A perspective from clinical trials	Biomolecules. 2021 Jan 13;11(1):Article number 97.
2021-01	c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation	Cancer Science. 2021 Jan;112(1):243-253.
2021-01	Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1	Pancreatology. 2021 Jan 10;21(1):192-199.
2020-12-29	Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan	PLoS ONE. 2020 Dec 29;15(12):Article number e0244487.
2020-11-13	The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort [Erraturm: Scientific Reports. 2020 May 4;10:Article number 7420.]	Scientific Reports. 2020 Nov 13;10:Article number 20199.
2020-10	Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study	Liver International. 2020 Oct;40(10):2535-2543.
2020-09	Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer	Annals of Oncology. 2020 Sep;31(Suppl. 4):S268-S269.
2020-09	Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study	Annals of Oncology. 2020 Sep;31(Suppl. 4):S1192.
2020-07-01	A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue	Haematologica. 2020 Jul 1;105(7):e349-e354.
2020-07	JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions	Annals of Oncology. 2020 Jul;31(7):861-872.
2020-05-26	Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan	Journal of Biomedical Science. 2020 May 26;27:Article number 69.
2020-05-04	The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort	Scientific Reports. 2020 May 4;10:Article number 7420.
2020-05	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data	Gastric Cancer. 2020 May;23(3):510-519.
2020-05	Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in patients with pretreated biliary tract cancer	Journal for ImmunoTherapy of Cancer. 2020 May;8(1):Article number e00056.
2020-05	Establishing the common oncology data model for the national biobank consortium of Taiwan	Journal of Clinical Oncology. 2020 May;38(15, Suppl.):Meeting Abstract e19283.
2020-05	EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435)	Journal of Clinical Oncology. 2020 May;38(15, Suppl.):Abstract number TPS4669.
2020-04	Management of early stage gastro-oesophageal cancers: Expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty	Expert Review of Anticancer Therapy. 2020 Apr;20(4):305-324.
2020-04	Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours	British Journal of Cancer. 2020 Apr;122(9):1324-1332.
2020-03	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO	Annals of Oncology. 2020 Mar;31(3):334-351.
2020-02	Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study	Cancer Science. 2020 Feb;111(2):513-527.
2020-02	Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study	Journal of Clinical Oncology. 2020 Feb;38(4):Meeting Abstract 477.
2020-02	A phase III study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Three-year update data	Journal of Clinical Oncology. 2020 Feb;38(4):Meeting Abstract 383.

顯示項目101-125 / 510. (共21頁) << < 1 2 3 4 5 6 7 8 9 10 > >> 每頁顯示[10|25|50]項目